Literature DB >> 16172856

Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.

Z Samra1, M Yardeni, N Peled, J Bishara.   

Abstract

To evaluate the species distribution and antifungal susceptibility of Candida isolates in a tertiary institution in Israel, all consecutive isolates of Candida spp. recovered from blood during the last 2 years were studied. The isolates were identified by the germ tube test and the API ID 32C test (bioMérieux, Marcy l'Etoile, France). MICs of antifungal agents were determined by the E test. Candida albicans was the most commonly isolated species, accounting for 44% (63/142) of the isolates, followed by Candida tropicalis (25%; 35/142), Candida parapsilosis (20%; 29/142), Candida glabrata (10%; 14/142), and Candida krusei (0.7%; 1/142). All isolates were sensitive to amphotericin B and voriconazole. Resistance to fluconazole (using a high MIC of >/=256 microg/ml) was found in 1.6% of C. albicans isolates, in 3.4% of C. parapsilosis isolates, and in 21.4% of C. glabrata isolates. Resistance to itraconazole was detected in 3.2% of C. albicans isolates, in 2.9% of C. tropicalis isolates, in 3.4% of C. parapsilosis isolates, and in 93% of C. glabrata isolates. Disparities in species distribution and antifungal susceptibility of Candida isolates from the institute studied versus Candida isolates from other centers and countries are described. The findings emphasize the need for continuous surveillance and further clinical investigational studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16172856     DOI: 10.1007/s10096-005-0005-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

Review 1.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

2.  Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada.

Authors:  G St-Germain; M Laverdière; R Pelletier; A M Bourgault; M Libman; C Lemieux; G Noël
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

3.  Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

4.  National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species.

Authors:  M A Pfaller; S A Messer; A Houston; M S Rangel-Frausto; T Wiblin; H M Blumberg; J E Edwards; W Jarvis; M A Martin; H C Neu; L Saiman; J E Patterson; J C Dibb; C M Roldan; M G Rinaldi; R P Wenzel
Journal:  Diagn Microbiol Infect Dis       Date:  1998-05       Impact factor: 2.803

5.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.

Authors:  M A Pfaller; D J Diekema; R N Jones; H S Sader; A C Fluit; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

6.  Risk Factors for Candida tropicalis fungemia in patients with cancer.

Authors:  D P Kontoyiannis; I Vaziri; H A Hanna; M Boktour; J Thornby; R Hachem; G P Bodey; I I Raad
Journal:  Clin Infect Dis       Date:  2001-09-24       Impact factor: 9.079

7.  National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.

Authors:  Shunji Takakura; Naoko Fujihara; Takashi Saito; Toyoichiro Kudo; Yoshitsugu Iinuma; Satoshi Ichiyama
Journal:  J Antimicrob Chemother       Date:  2003-12-19       Impact factor: 5.790

8.  Nosocomial candidemia in a university hospital in Taiwan.

Authors:  C C Hung; Y C Chen; S C Chang; K T Luh; W C Hsieh
Journal:  J Formos Med Assoc       Date:  1996-01       Impact factor: 3.282

9.  Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002.

Authors:  Jiun-Ling Wang; Shan-Chwen Chang; Po-Ren Hsueh; Yee-Chun Chen
Journal:  J Microbiol Immunol Infect       Date:  2004-08       Impact factor: 4.399

10.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

View more
  6 in total

1.  Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates.

Authors:  Dilek Yesim Metin; Suleyha Hilmioglu-Polat; Pinar Samlioglu; Biray Doganay-Oflazoglu; Ramazan Inci; Emel Tumbay
Journal:  Mycopathologia       Date:  2011-03-20       Impact factor: 2.574

2.  Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital.

Authors:  Xisto Sena Passos; Carolina Rodrigues Costa; Crystiane Rodrigues Araújo; Elisa Sales Nascimento; Lúcia Kioko Hasimoto e Souza; Orionalda de Fátima Lisboa Fernandes; Werther Souza Sales; Maria do Rosário Rodrigues Silva
Journal:  Mycopathologia       Date:  2007-03-01       Impact factor: 2.574

3.  Comparison of nosocomial candidemia of pediatric and adult cases in 2-years period at a Turkish university hospital.

Authors:  Asuman Birinci; Yeliz Tanriverdi Cayci; Kemal Bilgin; Murat Gunaydin; Cagatay Acuner; Saban Esen
Journal:  Eurasian J Med       Date:  2011-08

4.  Prevalence of Candida bloodstream isolates from patients in two hospitals in Vietnam.

Authors:  Nguyen Duy Bac; Le Tran Anh; Le Bach Quang; Nguyen Khac Luc; Tran Thi Thanh Nga; Minoru Nagi; Miyazaki Yoshitsugu; Hoang Thi Thu Ha; Dang Duc Anh; Do Quyet; Do Ngoc Anh
Journal:  Iran J Microbiol       Date:  2019-04

5.  Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea.

Authors:  Jin-Sol Lee; Jong Hee Shin; Kyungwon Lee; Mi-Na Kim; Bo-Moon Shin; Young Uh; Wee-Gyo Lee; Hye Soo Lee; Chulhun L Chang; Soo Hyun Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang
Journal:  Yonsei Med J       Date:  2007-10-31       Impact factor: 2.759

6.  Heparin-benzyl alcohol enhancement of biofilms formation and antifungal susceptibility of vaginal Candida species isolated from pregnant and nonpregnant Saudi women.

Authors:  Raid A Al-Akeel; Talat A El-Kersh; Yazeed A Al-Sheikh; Ziab Zakey Al-Ahmadey
Journal:  Bioinformation       Date:  2013-04-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.